Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct;10(10):928-930.
doi: 10.1016/S2213-2600(22)00222-3. Epub 2022 Jul 8.

Monoclonals for patients hospitalised with COVID-19

Jason M Pogue  1 , Erin K McCreary  2
Affiliations
Comment

Monoclonals for patients hospitalised with COVID-19

Jason M Pogue et al. Lancet Respir Med. 2022 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JMP discloses serving as a consultant to Merck, Shionogi, and Roche. EKM discloses serving as a consultant to Shionogi and is the Director of infectious diseases improvement and clinical research innovation at UPMC. In this role, EKM oversaw clinical trials involving use of sotrovimab (donated by GSK) and evaluation of tixagevimab–cilgavimab in outpatients (funded by AstraZeneca). She does not receive salary support or funding for her involvement in these trials.

Comment on

References

    1. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327:1236–1246. - PMC - PubMed
    1. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385:e81. - PMC - PubMed
    1. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632–644. - PMC - PubMed
    1. Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399:665–676. - PMC - PubMed
    1. Somersan-Karakaya S, Mylonakis E, Menon VP, et al. Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19. medRxiv. 2021 doi: 10.1101/2021.11.05.21265656. published online Jan 27, 2022. (preprint). - DOI - PMC - PubMed